Gleevec is in a clinical study: Therapy of HESPVAtypical CML or CMMLand Mastocytosis With Imatinib MesylateNCT00038675. The goal of this clinical research study is to see if Gleevecknown as imatinib mesylate (STI571)can improve the disease condition in patients with hypereosinophilic syndrome (HES)polycythemia veraatypical chronic myeloid leukemia (CML) or CMML with PDGF-R fusion genesor mastocytosis.
There is significant supporting evidence. Gleevec may be useful in those types of systemic mastocytosis (systemic mast cell disease) that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. Imatinib mesylate may also be useful in a subtype of systemic mastocytosis that carries the FIP1L1-PDGFRA rearrangement.
Pardanani AKetterling RPBrockman SRet al. CHIC2 deletiona surrogate for FIP1L1-PDGFRA fusionoccurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. Nov 1 2003;102(9):3093-6
Droogendijk HJKluin-Nelemans HJvan Doormaal JJOranje APvan de Loosdrecht AAvan Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51
Gleevec is in a clinical study: Therapy of HESPVAtypical CML or CMMLand Mastocytosis With Imatinib MesylateNCT00038675. The goal of this clinical research study is to see if Gleevecknown as imatinib mesylate (STI571)can improve the disease condition in patients with hypereosinophilic syndrome (HES)polycythemia veraatypical chronic myeloid leukemia (CML) or CMML with PDGF-R fusion genesor mastocytosis.
There is significant supporting evidence. Gleevec may be useful in those types of systemic mastocytosis (systemic mast cell disease) that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. Imatinib mesylate may also be useful in a subtype of systemic mastocytosis that carries the FIP1L1-PDGFRA rearrangement.
Pardanani AKetterling RPBrockman SRet al. CHIC2 deletiona surrogate for FIP1L1-PDGFRA fusionoccurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. Nov 1 2003;102(9):3093-6
Droogendijk HJKluin-Nelemans HJvan Doormaal JJOranje APvan de Loosdrecht AAvan Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51